International: +1-347-960-6455
Various Advancements in Drug Development Technologies are Beholding the Growth of Rectal Cancer Therapeutics Pipeline

According to a new research report “Rectal Cancer Therapeutics – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, rectal cancer therapeutics currently exhibits a proliferating pipeline with 10+ therapeutic candidates.

Rectal Cancer Therapeutics Pipeline Insights

Rectal cancer, also known as colon cancer, bowel cancer, or colorectal cancer, is the growth of malignant and cancerous cells in the lower part of the colon. This cancer first develops as polyp, which further becomes malignant. In general, rectal cancer occurs due to changes in DNA of healthy cells present in the rectum. However, in most cases, the cause of these changes is unknown. Some of the risk factors that can cause rectal cancer include aging, smoking, inflammatory bowel disease (IBD), family or personal history of colon or rectal cancer, and high fat diet or diet mostly from animal sources, alcohol consumption, and sedentary lifestyle. Commonly occurring symptoms of the cancer include bloody stool, abdominal pain, iron deficiency, diarrhea, and weight loss.

Furthermore, the prognosis of the cancer depends on its stage, and it can be diagnosed through physical examination, digital rectal examination, colonoscopy, carcinoembryonic antigen (CEA) assay, and biopsy. Chest X-rays and colonoscopy also help in determining the stage of the cancer. For the treatment of rectal cancer, the affected lymph node can be removed through surgery, depending on stage of the cancer. Other treatment options include chemotherapy and radiation therapy.

Erbitux (Eli Lilly and Company), Avastin (Genentech Inc.), Opdivo (Bristol-Myers Squibb Company) are some of the drugs approved by the Food and Drug Administration (FDA) for the treatment of rectal cancer.

Insights on Pipeline Segments

According to the research findings, majority of pipeline drug candidates are being developed for oral administration. It has been observed that the oral route of medications is convenient, available in delayed or rapid release formulation, less risk of systemic infections, and inexpensive in nature, and also provides improved patient’s compliance. Administration of therapeutics for rectal cancer through oral route has shown promising results in clinical studies.

Positive Clinical Trial Results are Expected to Drive Rectal Cancer Therapeutics Pipeline

Companies that are involved in developing therapeutics for rectal cancer have shown positive clinical results in the various phases of drug development. For instance, in 2017, Hutchison MediPharma announced positive topline result of trial of fruquintinib in 416 patients with locally advanced or metastatic colorectal cancer.

Designation Grants Play a Vital Role in Accelerating the Drug Development Process

In 2017, the FDA granted Orphan Drug Designation to tucatinib for the treatment of rectal cancer. Therefore, with the increasing number of designation grants, the overall rectal cancer therapeutics pipeline is expected to grow significantly in the upcoming years.

Strategic Advancements Play a Pivotal Role in the Rectal Cancer Therapeutic Development

In the wake of strategic development activities, companies are collaborating to evaluate antibody drug conjugate as a potential treatment for the disease. In April 2019, Evotec SE and Indivumed GmbH entered into a research collaboration to discover and develop therapeutics for the treatment of colorectal cancer. The collaboration, which runs for an initial term of two years, will combine Evotec’s proprietary bioinformatics analysis platform “PanHunter” as well as its small molecule and antibody discovery platforms with the CRC cohort of Indivumed’s true multi-omics cancer database “IndivuType”.

Browse report overview with detailed TOC on "Rectal Cancer Therapeutics – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments" at:

Eli Lilly and Company, Taiwan Liposome Company Ltd., Genentech Inc., Sanofi-aventis Groupe, Merck & Co. Inc., Bristol-Myers Squibb Company, Hutchison MediPharma, Seattle Genetics Inc., and Advaxis Inc. are some of the key players involved in the development of drugs for rectal cancer.

Rectal Cancer Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of rectal cancer. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the rectal cancer therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in the report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to rectal cancer.